Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

authored by: Werner Kulp, J. M. Graf Von Der Schulenburg, Wolfgang Greiner
Abstract: We investigated the cost-effectiveness of escitalopram (10 mg daily dose) vs. venlafaxine XR (75 mg daily dose) in a German outpatient setting for the treatment of unipolar depression (MADRS score 20-34) over a period of 70 days. To assess the cost effectiveness of the two substances we combined data from physician's surveys and clinical response data; cost-effectiveness was calculated using a Markov model. In a second step we considered the therapeutic decisions of the attending physicians. Cost-effectiveness was indicated as costs per successfully treated patient. Escitalopram demonstrated a more favorable cost-effectiveness ratio than venlafaxine XR. The analysis of treatment patterns showed that attending physicians intervene fairly early if the chosen therapy is ineffective. Additional costs for the use of venlafaxine XR over those of escitalopram were estimated from €7,446 to €9.836 per successfully treated per patient. Hence escitalopram may be a cost-effective alternative to venlafaxine XR in outpatient care setting in Germany.
Organisation(s): Institute of Insurance Business Administration
External Organisation(s): Bielefeld University
Type: Article
Journal: European Journal of Health Economics
Volume: 6
Pages: 317-321
No. of pages: 5
ISSN: 1618-7598
Publication date: 12.2005
Publication status: Published
Peer reviewed: Yes
ASJC Scopus subject areas: Economics, Econometrics and Finance (miscellaneous), Health Policy
Sustainable Development Goals: SDG 3 - Good Health and Well-being
Electronic version(s): https://doi.org/10.1007/s10198-005-0306-1 (Access: Closed)